HC Wainwright Reiterates Buy Rating for Benitec Biopharma (NASDAQ:BNTC)

Benitec Biopharma (NASDAQ:BNTC)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $28.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 90.87% from the stock’s previous close.

Several other analysts have also recently commented on the company. Guggenheim restated a “buy” rating and set a $17.00 target price on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, Robert W. Baird started coverage on shares of Benitec Biopharma in a research report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $24.43.

Benitec Biopharma Stock Up 2.3 %

NASDAQ:BNTC opened at $14.67 on Monday. The firm has a market cap of $344.03 million, a PE ratio of -9.72 and a beta of 0.92. Benitec Biopharma has a 12 month low of $4.75 and a 12 month high of $16.90. The company’s 50-day moving average price is $12.07 and its two-hundred day moving average price is $11.05.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.19. On average, research analysts expect that Benitec Biopharma will post -1.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Acuta Capital Partners LLC bought a new stake in shares of Benitec Biopharma during the third quarter worth approximately $274,000. Suvretta Capital Management LLC raised its position in shares of Benitec Biopharma by 422.0% during the 3rd quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company’s stock valued at $81,139,000 after acquiring an additional 7,137,763 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after acquiring an additional 20,012 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock valued at $37,123,000 after purchasing an additional 2,142,643 shares during the period. Finally, MYDA Advisors LLC bought a new position in shares of Benitec Biopharma in the 4th quarter worth $632,000. Institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.